Alpha Teknova (TKNO) Competitors

Alpha Teknova logo
$7.71 +0.06 (+0.78%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

TKNO vs. ALMR, AZTA, MRVI, FTRE, and BLFS

Should you buy Alpha Teknova stock or one of its competitors? Alpha Teknova's main competitors and comparable companies include Alamar Biosciences (ALMR), Azenta (AZTA), Maravai LifeSciences (MRVI), Fortrea (FTRE), and BioLife Solutions (BLFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Alpha Teknova compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Alpha Teknova (NASDAQ:TKNO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

In the previous week, Alamar Biosciences had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 5 mentions for Alamar Biosciences and 4 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.20 beat Alamar Biosciences' score of 0.79 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alamar Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alpha Teknova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alpha Teknova has a net margin of -34.76% compared to Alamar Biosciences' net margin of -48.22%. Alpha Teknova's return on equity of -24.95% beat Alamar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Alamar Biosciences-48.22% -78.71% -20.08%
Alpha Teknova -34.76%-24.95%-16.27%

Alpha Teknova has lower revenue, but higher earnings than Alamar Biosciences. Alpha Teknova is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alamar Biosciences$74.21M28.69-$29.82M-$2.15N/A
Alpha Teknova$40.52M11.88-$17.26M-$0.29N/A

Alamar Biosciences presently has a consensus price target of $33.00, suggesting a potential upside of 7.70%. Alpha Teknova has a consensus price target of $8.75, suggesting a potential upside of 14.38%. Given Alpha Teknova's higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Alamar Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alamar Biosciences
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

13.8% of Alpha Teknova shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Alpha Teknova beats Alamar Biosciences on 9 of the 13 factors compared between the two stocks.

How does Alpha Teknova compare to Azenta?

Azenta (NASDAQ:AZTA) and Alpha Teknova (NASDAQ:TKNO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

99.1% of Azenta shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Azenta had 36 more articles in the media than Alpha Teknova. MarketBeat recorded 40 mentions for Azenta and 4 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.20 beat Azenta's score of 0.60 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Azenta
7 Very Positive mention(s)
7 Positive mention(s)
16 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alpha Teknova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Azenta has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Azenta presently has a consensus price target of $47.60, suggesting a potential upside of 3.91%. Alpha Teknova has a consensus price target of $8.75, suggesting a potential upside of 14.38%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Azenta.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Azenta
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Azenta has a net margin of -26.86% compared to Alpha Teknova's net margin of -34.76%. Azenta's return on equity of 1.41% beat Alpha Teknova's return on equity.

Company Net Margins Return on Equity Return on Assets
Azenta-26.86% 1.41% 1.15%
Alpha Teknova -34.76%-24.95%-16.27%

Alpha Teknova has lower revenue, but higher earnings than Azenta. Alpha Teknova is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Azenta$621.70M3.23-$166.99M-$3.62N/A
Alpha Teknova$40.52M11.88-$17.26M-$0.29N/A

Summary

Azenta beats Alpha Teknova on 8 of the 15 factors compared between the two stocks.

How does Alpha Teknova compare to Maravai LifeSciences?

Alpha Teknova (NASDAQ:TKNO) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Alpha Teknova presently has a consensus price target of $8.75, suggesting a potential upside of 14.38%. Maravai LifeSciences has a consensus price target of $8.10, suggesting a potential upside of 11.26%. Given Alpha Teknova's higher possible upside, equities analysts plainly believe Alpha Teknova is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Maravai LifeSciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67

13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Maravai LifeSciences has a net margin of -30.83% compared to Alpha Teknova's net margin of -34.76%. Maravai LifeSciences' return on equity of -12.44% beat Alpha Teknova's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Teknova-34.76% -24.95% -16.27%
Maravai LifeSciences -30.83%-12.44%-6.66%

Alpha Teknova has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Alpha Teknova has higher earnings, but lower revenue than Maravai LifeSciences. Alpha Teknova is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Teknova$40.52M11.88-$17.26M-$0.29N/A
Maravai LifeSciences$185.74M10.19-$130.77M-$0.43N/A

In the previous week, Maravai LifeSciences had 6 more articles in the media than Alpha Teknova. MarketBeat recorded 10 mentions for Maravai LifeSciences and 4 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.20 beat Maravai LifeSciences' score of 1.14 indicating that Alpha Teknova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Teknova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maravai LifeSciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Maravai LifeSciences beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.

How does Alpha Teknova compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Fortrea currently has a consensus target price of $24.23, indicating a potential upside of 23.67%. Alpha Teknova has a consensus target price of $8.75, indicating a potential upside of 14.38%. Given Fortrea's higher probable upside, equities research analysts clearly believe Fortrea is more favorable than Alpha Teknova.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.46
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

13.8% of Alpha Teknova shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 13.2% of Alpha Teknova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alpha Teknova has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.72B0.69-$986.20M-$0.73N/A
Alpha Teknova$40.52M11.88-$17.26M-$0.29N/A

Fortrea has a net margin of -2.58% compared to Alpha Teknova's net margin of -34.76%. Fortrea's return on equity of 13.98% beat Alpha Teknova's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-2.58% 13.98% 2.76%
Alpha Teknova -34.76%-24.95%-16.27%

In the previous week, Fortrea had 5 more articles in the media than Alpha Teknova. MarketBeat recorded 9 mentions for Fortrea and 4 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.20 beat Fortrea's score of 0.58 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Alpha Teknova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fortrea has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Summary

Fortrea beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.

How does Alpha Teknova compare to BioLife Solutions?

Alpha Teknova (NASDAQ:TKNO) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Alpha Teknova has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 13.2% of Alpha Teknova shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioLife Solutions has a net margin of 53.29% compared to Alpha Teknova's net margin of -34.76%. BioLife Solutions' return on equity of 2.70% beat Alpha Teknova's return on equity.

Company Net Margins Return on Equity Return on Assets
Alpha Teknova-34.76% -24.95% -16.27%
BioLife Solutions 53.29%2.70%2.49%

In the previous week, Alpha Teknova had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 4 mentions for Alpha Teknova and 2 mentions for BioLife Solutions. Alpha Teknova's average media sentiment score of 1.20 beat BioLife Solutions' score of 1.13 indicating that Alpha Teknova is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alpha Teknova
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLife Solutions
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alpha Teknova presently has a consensus target price of $8.75, suggesting a potential upside of 14.38%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 18.74%. Given Alpha Teknova's stronger consensus rating and higher probable upside, research analysts clearly believe Alpha Teknova is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpha Teknova
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
BioLife Solutions
0 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.09

BioLife Solutions has higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Teknova$40.52M11.88-$17.26M-$0.29N/A
BioLife Solutions$106.69M17.71-$4.59M$1.1633.28

Summary

BioLife Solutions beats Alpha Teknova on 10 of the 16 factors compared between the two stocks.

Get Alpha Teknova News Delivered to You Automatically

Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TKNO vs. The Competition

MetricAlpha TeknovaLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$484.96M$10.83B$7.65B$11.69B
Dividend YieldN/A1.46%2.47%4.46%
P/E Ratio-26.5951.4533.9329.91
Price / Sales11.977.618.455.70
Price / CashN/A26.5521.0121.90
Price / Book8.124.424.473.74
Net Income-$17.26M$57.47B$3.51B$393.98M
7 Day Performance-10.56%-4.09%-5.96%-5.71%
1 Month Performance8.90%-0.69%-4.39%-7.03%
1 Year Performance74.83%20.09%-1.32%-7.26%

Alpha Teknova Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TKNO
Alpha Teknova
3.2176 of 5 stars
$7.71
+0.8%
$8.75
+13.5%
+78.7%$484.96M$40.52MN/A158
ALMR
Alamar Biosciences
2.3432 of 5 stars
$31.42
-0.3%
$33.00
+5.0%
N/A$2.18B$74.21MN/A222
AZTA
Azenta
1.8937 of 5 stars
$49.35
+21.9%
$41.20
-16.5%
+56.0%$2.16B$593.82MN/A3,000
MRVI
Maravai LifeSciences
1.9116 of 5 stars
$7.93
+0.8%
$7.38
-6.9%
+118.0%$2.06B$185.74MN/A410
FTRE
Fortrea
4.1946 of 5 stars
$21.11
-1.3%
$24.23
+14.8%
+100.1%$2.04B$2.67BN/A14,300

Related Companies and Tools


This page (NASDAQ:TKNO) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners